Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483405 | 0.85 | RAB9A (0.56) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6484249 | 0.80 | MAPT (0.56) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6486104 | 0.77 | GAA (0.56) | MAPTGAASMN1; SMN2LMNAHTT | |
| SCHEMBL6496178 | 0.77 | MAPT (0.65) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6480990 | 0.76 | MAPT (0.57) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6096534 | 0.75 | GAA (0.73) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6483600 | 0.74 | GAA (0.58) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6491666 | 0.73 | KDM4E (0.54) | MAPTGAASMN1; SMN2POLBLMNA | |
| SCHEMBL6481742 | 0.73 | MAPT (0.50) | MAPTGAALMNAHTTNPC1 | |
| SCHEMBL8491546 | 0.72 | MAPT (0.60) | MAPTGAASMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2004-07-01 | — | — | US | claimed |
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2003-01-16 | — | — | US | claimed |
| WO-1999011638-A1 | SUBSTITUTED 1-ARYL-3- HETEROARYL-THIOUREAS AND SUBSTITUTED 1-ARYL-3-HETEROARYL-ISOTHIOUREAS AS ANTIATHEROSCLEROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-03-11 | — | — | WO | claimed |
| US-6936630-B2 | Substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2004-07-01 | — | — | US | disclosed |
| US-6686476-B2 | ANTICHOILESTEROL AGENTS; CARDIOVASCULAR DISORDERS | WYETH | 2004-02-03 | — | — | US | disclosed |
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2003-01-16 | — | — | US | disclosed |
| US-6455566-B1 | Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents | WYETH | 2002-09-24 | — | — | US | disclosed |
| WO-1999011638-A1 | SUBSTITUTED 1-ARYL-3- HETEROARYL-THIOUREAS AND SUBSTITUTED 1-ARYL-3-HETEROARYL-ISOTHIOUREAS AS ANTIATHEROSCLEROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | CBR1, LDLR, HMGCR | MAPT 4780/4885GAA 3175/4885SMN1; SMN2 4763/4885 |
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | CBR1, LDLR, HMGCR | MAPT 4780/4885GAA 3175/4885SMN1; SMN2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.